Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study

Aims SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study, investigated once‐weekly semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and Methods Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 wee...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2023-06, Vol.25 (6), p.1658-1667
Hauptverfasser:	Napoli, Raffaele, Berra, Cesare, Catarig, Andrei‐Mircea, Di Loreto, Chiara, Donatiello, Emily, Berentzen, Tina Landsvig, Pitocco, Dario, Giorgino, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antidiabetics Body Weight Body weight loss Clinical medicine Confidence intervals Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - chemically induced Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy GLP‐1 analogue Glucagon-Like Peptides - adverse effects glycaemic control Glycated Hemoglobin Hemoglobin Humans Hypoglycemic Agents - adverse effects Observational studies observational study Patients Prospective Studies real‐world evidence semaglutide type 2 diabetes Weight Loss
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study, investigated once‐weekly semaglutide in patients with type 2 diabetes (T2D) in routine clinical practice. Materials and Methods Adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) level within 12 weeks of semaglutide initiation were enrolled. The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30 weeks). Other endpoints included changes in body weight, waist circumference and patient‐reported outcomes, and the proportion of patients achieving HbA1c
ISSN:	1462-8902 1463-1326
DOI:	10.1111/dom.15020